Clinical Trials
An open-label, single-arm clinical study of FST-100 demonstrated preliminary safety and efficacy in patients with microbiologically confirmed adenoviral conjunctivitis. Results from this study suggested both the alleviation of clinical symptoms associated with inflammation as well as viral eradication.
Adenoviral Conjunctivitis
Foresight Biotherapeutics is conducting additional clinical trials of FST-100 for adenoviral conjunctivitis.
To request more information, .
Otic Indications
Foresight Biotherapeutics is conducting trials with FST-201 in various otic indications.
To request more information, .